Overall, epithelial ovarian cancers have a five-year relative survival rate of 48 percent. This means that on average, people with epithelial ovarian tumors are about half as likely as people without this cancer to live at least five years. However, a person’s prognosis also depends on how far cancer has spread.
The most common symptoms include:
Signs and symptoms of ovarian cancer may include:
What is my Personal Risk of Ovarian Cancer?
41.
Malignant neoplasm of unspecified ovary C56. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C56. 9 became effective on October 1, 2021.
42 for Squamous cell carcinoma of skin of scalp and neck is a medical classification as listed by WHO under the range - Malignant neoplasms .
ICD-10-CM Code for Personal history of malignant neoplasm of other parts of uterus Z85. 42.
ICD-10 code Z85. 43 for Personal history of malignant neoplasm of ovary is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
C56. 9, Malignant neoplasm of unspecified ovary.
Basal cell carcinoma of skin, unspecified C44. 91 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM C44. 91 became effective on October 1, 2021.
610 for Atypical squamous cells of undetermined significance on cytologic smear of cervix (ASC-US) is a medical classification as listed by WHO under the range - Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified .
Squamous cell carcinoma - a very common form of nonmelanoma skin cancer that originates in the squamous cells - becomes metastatic when it spreads (metastasizes) beyond the primary cancer site and affects other areas of the body.
N80. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM N80.
ICD-10 Code for Malignant neoplasm of endometrium- C54. 1- Codify by AAPC.
Z90. 710 - Acquired absence of both cervix and uterus | ICD-10-CM.
Unspecified ovarian cyst, left side N83. 202 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM N83. 202 became effective on October 1, 2021.
ICD-10 code N83. 20 for Unspecified ovarian cysts is a medical classification as listed by WHO under the range - Diseases of the genitourinary system .
ICD-10 code Z51. 11 for Encounter for antineoplastic chemotherapy is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Signs and symptoms of ovarian cancer may include:Abdominal bloating or swelling.Quickly feeling full when eating.Weight loss.Discomfort in the pelvic area.Fatigue.Back pain.Changes in bowel habits, such as constipation.A frequent need to urinate.
For more context, consider the meanings of “current” and “history of” (ICD-10-CM Official Guidelines for Coding and Reporting; Mayo Clinic; Medline Plus, National Cancer Institute):#N#Current: Cancer is coded as current if the record clearly states active treatment is for the purpose of curing or palliating cancer, or states cancer is present but unresponsive to treatment; the current treatment plan is observation or watchful waiting; or the patient refused treatment.#N#In Remission: The National Cancer Institute defines in remission as: “A decrease in or disappearance of signs or symptoms of cancer. Partial remission, some but not all signs and symptoms of cancer have disappeared. Complete remission, all signs and symptoms of cancer have disappeared, although cancer still may be in the body.”#N#Some providers say that aromatase inhibitors and tamoxifen therapy are applied during complete remission of invasive breast cancer to prevent the invasive cancer from recurring or distant metastasis. The cancer still may be in the body.#N#In remission generally is coded as current, as long as there is no contradictory information elsewhere in the record.#N#History of Cancer: The record describes cancer as historical or “history of” and/or the record states the current status of cancer is “cancer free,” “no evidence of disease,” “NED,” or any other language that indicates cancer is not current.#N#According to the National Cancer Institute, for breast cancer, the five-year survival rate for non-metastatic cancer is 80 percent. The thought is, if after five years the cancer isn’t back, the patient is “cancer free” (although cancer can reoccur after five years, it’s less likely). As coders, it’s important to follow the documentation as stated in the record. Don’t go by assumptions or averages.
According to the ICD-10 guidelines, (Section I.C.2.m):#N#When a primary malignancy has been excised but further treatment, such as additional surgery for the malignancy, radiation therapy, or chemotherapy is directed to that site, the primary malignancy code should be used until treatment is complete.#N#When a primary malignancy has been excised or eradicated from its site, there is no further treatment (of the malignancy) directed to that site, and there is no evidence of any existing primary malignancy, a code from category Z85, Personal history of malignant neoplasm, should be used to indicate the former site of the malignancy.#N#Section I.C.21.8 explains that when using a history code, such as Z85, we also must use Z08 Encounter for follow-up examination after completed treatment for a malignant neoplasm. This follow-up code implies the condition is no longer being actively treated and no longer exists. The guidelines state:#N#Follow-up codes may be used in conjunction with history codes to provide the full picture of the healed condition and its treatment.#N#A follow-up code may be used to explain multiple visits. Should a condition be found to have recurred on the follow-up visit, then the diagnosis code for the condition should be assigned in place of the follow-up code.#N#For example, a patient had colon cancer and is status post-surgery/chemo/radiation. The patient chart notes, “no evidence of disease” (NED). This is reported with follow-up code Z08, first, and history code Z85.038 Personal history of other malignant neoplasm of large intestine, second. The cancer has been removed and the patient’s treatment is finished.
This follow-up code implies the condition is no longer being actively treated and no longer exists. The guidelines state: Follow-up codes may be used in conjunction with history codes to provide the full picture of the healed condition and its treatment. A follow-up code may be used to explain multiple visits.
History of Cancer: The record describes cancer as historical or “history of” and/or the record states the current status of cancer is “cancer free,” “no evidence of disease,” “NED,” or any other language that indicates cancer is not current. According to the National Cancer Institute, for breast cancer, the five-year survival rate ...
The fear is, history of will be seen as a less important diagnosis, which may affect relative value units . Providers argue that history of cancer follow-up visits require meaningful review, examinations, and discussions with the patients, plus significant screening and watching to see if the cancer returns.
ICD-10 requires you to code to the greatest degree of specificity. If you have bilateral ovarian cancer, you should use BOTH the right ovarian cancer (C56.1) and the left ovarian cancer (C56.2) codes. The unspecified code (C56.9) might be appropriate for a patient diagnosed on biopsy if it is impossible to determine a site of origin.
For example, a stage 4 ovarian cancer may be coded using 3 codes: C56.1 (malignant neoplasm of the right ovary), C78.6 (secondary malignancy of the peritoneum and retroperitoneum, and J91.0 (malignant pleural effusion). How do you code for borderline ovarian tumors ...
In 2018, the CPT code 38573 (Laparoscopy, surgical ; with bilateral total pelvic lymphadenectomy and peri-aortic lymph node sampling, peritoneal washings, peritoneal biopsy (ies), omentectomy, and diaphragmatic washings, including diaphragmatic and other serosal biopsy (ies), when performed.) was created to address situation where a Gyn Onc is asked to perform staging where another surgeon has performed the laparoscopic BSO ± hysterectomy.
For a laparoscopic BSO with staging (for a patient with prior hysterectomy, for instance), you can use the CPT code 38573 (Laparoscopy, surgical; with bilateral total pelvic lymphadenectomy and peri-aortic lymph node sampling, peritoneal washings, peritoneal biopsy (ies), omentectomy, and diaphragmatic washings, including diaphragmatic and other serosal biopsy (ies), when performed) with a -22 modifier. That would be billed with the laparoscopic BSO CPT code 58661 with the -59 modifier for a second surgery. With any -22 modifier, you would need to have an operative note and letter requesting increased reimbursement with the rationale, in this case the extra time and effort for “debulking”.
This code specifically excludes hysterectomy codes. If you perform a laparoscopic hysterectomy, BSO, debulking, the proper CPT code would be 58575 (Laparoscopy, surgical, total hysterectomy for resection of malignancy (tumor debulking), with omentectomy including salpingo-oophorectomy, unilateral or bilateral, when performed).
The operative report documentation should clearly describe the procedure and the reason for performing it. You should also append a distinct ICD code, such as C78.5, secondary malignant neoplasm of the large bowel.
The series 58950-58952 can only be used with ICD10 codes for ovarian, tubal or primary peritoneal malignancy. 58953-58954 may be used with any diagnosis. All describe various combinations of procedures commonly performed for advanced gynecologic cancers.